synergistic effect in treating the disorder.

9. The combination of any one of claims 1 -7 wherein the compound of formula Ia or the salt thereof is to be administered simultaneously with the vemurafenib or the salt thereof.

10. The combination of any one of claims 1-7 wherein the compound of formula Ia or the salt and the vemurafenib or the salt thereof are to be administered sequentially.

11. A compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1, for therapeutic use for improving the quality of life of a patient treated for a hyperproliferative disorder with vemurafenib or a pharmaceutically acceptable salt thereof.

12. ~~A method for treating a disease or condition modulated by BRAF V600E mutation and high pAKT levels in a mammal comprising, administering to the mammal,~~ Use of a) a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1; and b) vemurafenib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or condition modulated by BRAF V600E mutation and high pAKT levels in a mammal.

13. The ~~method~~ use of claim 12, wherein the patient previously received vemurafenib single agent therapy.

14. The use of a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1 in the preparation of a medicament for the treatment of a hyperproliferative disorder in a mammal, wherein vemurafenib is to be administered to the mammal.

15. The use of a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1 in the preparation of a medicament for the treatment of a disease or condition modulated by AKT kinase in a mammal, wherein vemurafenib is to be administered to the mammal.